Study Overview
Sex: All
Age: 18 Years / N/A
No Study Documents
Study Overview
Sex: All
Age: 18 Years / N/A
No Study Documents
Completed
Study of Ociperlimab (BGB-A1217) in Combination with Tislelizumab in Advanced Solid Tumors
Beigene Study ID
ClinicalTrials.gov ID
Sex: All
Age: 18 Years / N/A
No Study Documents
Sex: All
Age: 18 Years / N/A
No Study Documents